aducanumab (Aduhelm) Report issue

Biologics mAb Approved FDA Fast Track FDA Accelerated Approval FDA
AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW
  • Now
Aducanumab, sold under the brand name Aduhelm, is a medication designed to treat Alzheimer's disease (AD). It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. It was developed by Biogen and Eisai.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

aducanumab | biib0307 | biib037 | biib-037

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (1)


 

Alzheimer Disease (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Alzheimer Disease (Phase 3)

Cognitive Dysfunction (Phase 3)

Healthy Volunteers (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue